IL-1beta, IL-6 and TNF-alpha and outcomes of neonatal hypoxic ischemic encephalopathy.
The role of cytokines in the pathogenesis of brain injury and their relation to neurological outcomes of asphyxiated neonates is not fully defined. We hypothesize that interleukin-1 beta (IL-1beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in cerebrospinal fluid (CSF) correlate with the severity of brain injury and can predict neurological deficits in infants who suffered from hypoxic ischemic encephalopathy (HIE). A prospective study was conducted on 24 term infants diagnosed with HIE and 13 controls. HIE was clinically classified into mild, moderate and severe according to Sarnat and Sarnat grading. Blood and CSF samples were obtained from all infants in the first 24h of life as part of routine investigations for suspected meningitis and/or sepsis. Neurological examination and Denver Developmental Screening Test II (DDST II) were performed at 6 and 12 months of life. IL-1beta, IL-6 and TNF-alpha were all significantly increased in HIE infants when compared to control. IL-1beta in the CSF correlated with the severity of HIE (r=0.61, P=0.001) more than IL-6 (r=0.45, P=0.004) or TNF-alpha (r=0.47, P=0.003). IL-1beta exhibited the highest CSF/serum ratio among the three studied cytokines suggesting its local release in the brain after the initial hypoxic injury. Abnormal neurological findings and/or abnormal DDST II at 6 and 12 months were best predicted by IL-1beta in the CSF (sensitivity=88% and specificity=80%). This study confirms the role of IL-1beta in the ongoing neuronal injury that occurs in the latent phase following the original HIE insult.
Aly
Hany
H
Department of Newborn Services, The George Washington University Hospital, 900 23rd Street, NW, Washington, DC 20037, USA. haly@mfa.gwu.edu
Khashaba
Mohamed T
MT
El-Ayouty
Mostafa
M
El-Sayed
Osman
O
Hasanein
Bothina M
BM
D001238:Asphyxia Neonatorum / Q000209:etiology; D002545:Brain Ischemia / Q000097:blood / Q000134:cerebrospinal fluid / Q000276:immunology*; D002657:Child Development; D005260:Female; D006801:Humans; D020925:Hypoxia-Ischemia, Brain / Q000097:blood / Q000134:cerebrospinal fluid / Q000276:immunology*; D007231:Infant, Newborn; D007375:Interleukin-1 / Q000097:blood / Q000134:cerebrospinal fluid*; D015850:Interleukin-6 / Q000097:blood / Q000134:cerebrospinal fluid*; D008297:Male; D009460:Neurologic Examination; D012016:Reference Values; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000134:cerebrospinal fluid
D007375:Interleukin-1; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha